Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Bowtell DD., Böhm S., Ahmed AA., Aspuria PJ., Bast RC., Beral V., Berek JS., Birrer MJ., Blagden S., Bookman MA., Brenton JD., Chiappinelli KB., Martins FC., Coukos G., Drapkin R., Edmondson R., Fotopoulou C., Gabra H., Galon J., Gourley C., Heong V., Huntsman DG., Iwanicki M., Karlan BY., Kaye A., Lengyel E., Levine DA., Lu KH., McNeish IA., Menon U., Narod SA., Nelson BH., Nephew KP., Pharoah P., Powell DJ., Ramos P., Romero IL., Scott CL., Sood AK., Stronach EA., Balkwill FR.
High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.